An antibody based therapy presenting synergism with conventional chemotherapy. The synergistic effect was invented at the Weizmann Institute.

The first innovative drug to be developed in Israel and to receive FDA approval, Copaxone® is a unique multiple sclerosis immunomodulator: the first and only non-interferon agent for the treatment